Business Description
Newland Pharmaceutical Co Ltd
ISIN : CNE1000065K2
Share Class Description:
SZSE:301277: Class ACompare
Compare
Traded in other countries / regions
301277.China IPO Date
2022-11-16Description
Newland Pharmaceutical Co Ltd is engaged in the research and development, production and sales of chiral pharmaceutical intermediates.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 784.19 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-EBITDA | 0.01 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 12.83 | |||||
| Beneish M-Score | -2.83 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.7 | |||||
| 3-Year EBITDA Growth Rate | -0.3 | |||||
| 3-Year EPS without NRI Growth Rate | -3.7 | |||||
| 3-Year FCF Growth Rate | 57.5 | |||||
| 3-Year Book Growth Rate | 51.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.27 | |||||
| 9-Day RSI | 46.84 | |||||
| 14-Day RSI | 48.62 | |||||
| 6-1 Month Momentum % | 8.97 | |||||
| 12-1 Month Momentum % | -3.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.39 | |||||
| Quick Ratio | 6.18 | |||||
| Cash Ratio | 4.39 | |||||
| Days Inventory | 28.35 | |||||
| Days Sales Outstanding | 63.4 | |||||
| Days Payable | 105.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.67 | |||||
| Dividend Payout Ratio | 0.68 | |||||
| Forward Dividend Yield % | 2.67 | |||||
| 5-Year Yield-on-Cost % | 2.71 | |||||
| 3-Year Average Share Buyback Ratio | -10.1 | |||||
| Shareholder Yield % | 2.74 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 40.11 | |||||
| Operating Margin % | 25.6 | |||||
| Net Margin % | 23.49 | |||||
| FCF Margin % | 19.34 | |||||
| ROE % | 11.14 | |||||
| ROA % | 9.76 | |||||
| ROIC % | 21.9 | |||||
| ROC (Joel Greenblatt) % | 43.67 | |||||
| ROCE % | 12.78 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 25.79 | |||||
| PE Ratio without NRI | 25.53 | |||||
| Price-to-Owner-Earnings | 47.79 | |||||
| PEG Ratio | 1.43 | |||||
| PS Ratio | 6.03 | |||||
| PB Ratio | 2.78 | |||||
| Price-to-Tangible-Book | 2.85 | |||||
| Price-to-Free-Cash-Flow | 31.77 | |||||
| Price-to-Operating-Cash-Flow | 16.64 | |||||
| EV-to-EBIT | 17.32 | |||||
| EV-to-EBITDA | 17.32 | |||||
| EV-to-Revenue | 4.78 | |||||
| EV-to-FCF | 25.03 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.64 | |||||
| Price-to-Graham-Number | 1.8 | |||||
| Price-to-Net-Current-Asset-Value | 4.47 | |||||
| Price-to-Net-Cash | 7.32 | |||||
| Earnings Yield (Greenblatt) % | 5.77 | |||||
| FCF Yield % | 3.21 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Newland Pharmaceutical Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 698.584 | ||
| EPS (TTM) (Â¥) | 0.582 | ||
| Beta | 0 | ||
| Volatility % | 40.3 | ||
| 14-Day RSI | 48.62 | ||
| 14-Day ATR (Â¥) | 0.598787 | ||
| 20-Day SMA (Â¥) | 15.166 | ||
| 12-1 Month Momentum % | -3.68 | ||
| 52-Week Range (Â¥) | 9.3 - 18.38 | ||
| Shares Outstanding (Mil) | 280.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Newland Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Newland Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Newland Pharmaceutical Co Ltd Frequently Asked Questions
What is Newland Pharmaceutical Co Ltd(SZSE:301277)'s stock price today?
The current price of SZSE:301277 is ¥15.01. The 52 week high of SZSE:301277 is ¥18.38 and 52 week low is ¥9.30.
When is next earnings date of Newland Pharmaceutical Co Ltd(SZSE:301277)?
The next earnings date of Newland Pharmaceutical Co Ltd(SZSE:301277) is .
Does Newland Pharmaceutical Co Ltd(SZSE:301277) pay dividends? If so, how much?
The Dividend Yield %  of Newland Pharmaceutical Co Ltd(SZSE:301277) is 2.67% (As of Today), Highest Dividend Payout Ratio of Newland Pharmaceutical Co Ltd(SZSE:301277) was 0.7. The lowest was 0.68. And the median was 0.7. The  Forward Dividend Yield % of Newland Pharmaceutical Co Ltd(SZSE:301277) is 2.67%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers